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Abstract: Plasmodium falciparum histidine-rich protein 2 (Pf HRP 2) was selected in this work as
the biomarker for the detection and diagnosis of malaria. An enzyme-linked immunosorbent assay
(ELISA) was first developed to evaluate the immunoreagent’s suitability for the sensor’s development.
A gold-based sensor with an integrated counter and an Ag/AgCl reference electrode was first
selected and characterised and then used to develop the immunosensor for Pf HRP 2, which enables
a low cost, easy to use, and sensitive biosensor for malaria diagnosis. The sensor was applied to
immobilise the anti-Pf HRP 2 monoclonal antibody as the capture receptor. A sandwich ELISA
assay format was constructed using horseradish peroxidase (HRP) as the enzyme label, and the
electrochemical signal was generated using a 3, 3′, 5, 5′ tetramethyl-benzidine dihydrochloride
(TMB)/H2O2 system. The performance of the assay and the sensor were optimised and characterised,
achieving a PfHRP 2 limit of detection (LOD) of 2.14 ng·mL−1 in buffer samples and 2.95 ng·mL−1 in
100% spiked serum samples. The assay signal was then amplified using gold nanoparticles conjugated
detection antibody-enzyme and a detection limit of 36 pg·mL−1 was achieved in buffer samples and
40 pg·mL−1 in serum samples. This sensor format is ideal for malaria detection and on-site analysis
as a point-of-care device (POC) in resource-limited settings where the implementation of malaria
diagnostics is essential in control and elimination efforts.
Keywords: Malaria; Pf HRP 2; parasites; immunosensor; biosensor; nanoparticles
1. Introduction
Malaria is a serious disease that is caused by an Apicomplexan Plasmodium parasite that is
transmitted by adult female Anopheles mosquitoes, which thrive in tropical and subtropical weather [1].
Malaria affects approximately 50% of the world’s population, and causes millions of deaths [2].
According to the latest World Health Organisation (WHO), estimates, released in December 2016,
there were 212 million cases of malaria in 2015, and 429,000 deaths [2]. From this, the African region
accounted for the most global cases of malaria (88%), followed by the South-East Asia Region (10%)
and the Eastern Mediterranean Region (2%). Despite control efforts, the disease continues to affect
productivity, and therefore an effective diagnosis is required for the successful treatment and reduction
of both complications and mortality [2].
The methods available for the detection of malaria include blood film microscopy, immune-
chromatographic tests, and serological tests. Blood film microscopy shows the highest specificity, as it
depends on the detection of Plasmodium parasites in blood circulation, and in some cases is essential for
epidemiological purposes [3]. This assay is known as the gold standard method for malaria diagnosis
despite problems with its field accuracy, unacceptably high false-positive rates, errors in species
identification, and its operator-dependence [4,5]. Alternative methods, such as laser desorption mass
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spectroscopy (LDMS), loop mediated isothermal amplification (LAMP), and flow cytometry (FCM) are
expensive, time consuming, require specialised training, and are characterised by various levels of
sensitivity or specificity in relation to sample quality [6–8]. Levels of parasitemia are not necessarily
correlative with the progression of the disease, particularly when the parasite is able to adhere to blood
vessel walls. Therefore, more sensitive, easy to use diagnostic tools need to be developed in order to
detect low levels of parasitemia in the field [9].
Serological malaria tests are blood tests that picks up the specific malaria antibodies produced by
the immune system [10]. These methods have a specific use, as they are limited to the measurement of
past exposure to the disease. Methods based on parasite nucleic acid detection [11] have shown great
sensitivity and specificity, but require significant infrastructure and training, and are more expensive
than the blood smear method [12]. Methods based on the use of antibodies to recognise parasite
components or biomarkers have also emerged in recent years [13].
Plasmodium falciparum histidine-rich protein 2 (Pf HRP 2) is a 35 kDa protein comprising unique
tandem repeats (Ala-His-His-Ala-Ala-Asp), and is present in the serum of a malaria-infected patient as
a parasite antigen [14,15]. Pf HRP 2 is also present in food vacuole [16], digestive vacuole [17], and
the membrane surface of the infected red blood cells [18]. Pf HRP 2 is produced in large amounts
by the most lethal of malaria parasites, and is specific to Plasmodium falciparum. Other malaria
biomarkers, such as parasite lactate dehydrogenase (pLDH), and/or parasite aldolase, are common
to all Plasmodium species [19]. In addition, Pf HRP2 has been proven to be useful in detecting the
presence of parasites in cases of placental malaria [20]. The significance of Pf HRP 2 has led to a
lateral flow dipstick test [21,22], enzyme-linked immunosorbent assay (ELISA) tests [4], and Western
blotting [23] for the clinical diagnosis of malaria in support of microscopy. The drawbacks of these
techniques are that they are either of low sensitivity, which could lead to inappropriately withholding
treatment from patients with malaria [19], or are as time consuming as the lab-based methods. Recent
literature has reported the development of different sensors for malaria based on biomarker and
antibody detection [24,25]. Therefore, in this work, we investigated the development of a rapid and
highly sensitive sensor based on a screen-printed device, which would enable its use in low-resource
countries. The method selected was based on chronoamperometry, which is well known for its
high sensitivity [26] and ability to amplify a signal using nanotechnology. The use of biomarker
detection related to parasite infection was also implemented in this work through the selection of
Pf HRP 2. The biosensor was then optimised to achieve a sensitive outcome and a capacity to work in
resource-limited settings, and can be combined with other biomarkers for malaria infection detection.
2. Materials and Methods
2.1. Materials
Plasmodium falciparum histidine-rich protein 2 recombinant protein (PIP001), sandwich pair
HuCAL capture monoclonal antibody (HCA 160, IgG1, clone 14971), and detection (HCA 159, IgG1,
clone 14964) monoclonal antibody conjugated to horseradish peroxidase (HRP) were purchased from
AbDSerotec (UK). Phosphate buffered saline tablets (PBS, pH 7.4), PBST (0.05 v/v Tween-20), Tween-20,
microtitre plates, and MaxiSorp (Nunc Immuno), were purchased from Thermo Fischer Scientific
(Hertfordshire, UK). Bovine serum albumin (BSA), phosphate citrate buffer tablets, sodium hydroxide,
potassium chloride (KCl), sodium carbonate, sodium bicarbonate, 3, 3′, 5, 5′-tetramethyl benzidine
hydrochloride hydrate (TMB) (powder), colloidal gold, hydrogen peroxide, 95% ethanol, potassium
ferricyanide [K3Fe(CN)6], and human serum were purchased from Sigma-Aldrich (Dorset, UK). Milk
concentrate blocking solution was purchased from KPL (Gaithersburg, MD, USA). Double-distilled
ultrapure water produced by a Millipore Direct-Q® 3 UV (Millipore; Molsheim, France) was used
for the analysis. All of the chemicals and solvents were of analytical or HPLC grade, and were used
without further purification.
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2.2. Sensors Fabrication and Electrochemical Measurements
Screen-printed gold electrodes (SPGE), consisting of a gold working electrode, a carbon counter
and a silver–silver chloride pseudo-reference electrode were fabricated using a procedure similar to
that described by Noh and Tothill [27], and printed using the facilities at DuPont with inks provided
by the company (DuPont Microcircuit Materials, Bristol, UK). Three electrode batches, JD1, JD2a, and
JD2b, were tested. The printing pastes used for JD1 were BQ221 carbon, BQ331 gold, 5880 Ag/AgCl,
and 5036 blue encapsulant (DuPont Ltd. Bristol, UK), produced in 2010. JD2a and JD2b were different
from JD1 in that the carbon ink used was BQ226, but all other inks used were the same as JD1. The JD2a
sensors were from a batch produced in 2013, while the JD2b sensors were freshly produced (2015).
The gold working electrode had a 5 mm diameter, giving a 19.6 mm2 planar area, and was printed on
a graphite ink layer (dried at 120 ◦C, 30 min).
The electrochemical procedures were conducted using a computer-controlled four channel
Autolab electrochemical analyser multipotentiostat (Metrohm, The Netherlands) throughout, which
allows the simultaneous detection of four sensors. Data capture was through the supplied GPES
version 4.9) software installed onto a personal computer (PC). The sensor edge connectors were from
PalmSens (Provided by Alvatek, Gloucestershire, UK). The electrodes were characterised using cyclic
voltammetry (CV) and chronoamprometry. The CV scans were conducted by using a 100 µL drop
of potassium ferricyanide (K4Fe(CN)63H2O) at 0.1, 0.5, and 1 mM in 0.1 M KCl, placed onto the
electrode’s surface. Three scans were taken at varying scan rates (10, 20, 50, 70, and 100 mV·s−1)
relative to the on board Ag/AgCl reference electrodes. The active area of the working electrode was
calculated [28] using the Randles–Sevcik equation [29].
For sample analysis, each of the measurements was carried out in triplicate using a new strip
in a non-deaerated and unstirred solution. For the selection of the optimal constant potential for the
enzymatic reaction (TMB-H2O2-HRP), choroamperometry was conducted using a bare screen-printed
gold electrode with buffer solution (50 mM phosphate citrate buffer, pH 5.0, in 0.1 M KCl) and
a substrate (4 mM TMB, 0.06% H2O2) with an antibody-HRP conjugate. Step amperometry was
conducted at a range of potentials from +600 mV to −400 mV within 600 s for the TMB-H2O2-HRP
system, in order to achieve the best signal-to-noise ratio. Data plotted from the steady state current
was used to obtain the concentration of the analyte. Following the measurements, the data were copied
to Microsoft Excel for representation.
2.3. SEM and AFM Scan of the SPGE
Scanning electron microscope (SEM) (Phillips, Guildford, UK) was used to visualise the surface
structure of the gold working electrode at 50× and 3500× magnification. An electron emission
spectrum was also obtained by using the Environmental Scanning Electron Microscope (ESEM) to
determine the composition of the SPGE. Atomic force microscopy (AFM) (Digital instruments, Boston,
MA, USA) was used to obtain the sensor’s surface topography at 25 and 50 mu magnification.
2.4. Immunoassay Development (ELISA)
ELISA tests were first developed using micro well polystyrene plates, MaxiSorp (Nunc
Immuno). A direct assay was first developed by adapting the standard ELISA AbDSerotec protocol
(Abdserotec.com). Following optimisation, Pf HRP 2 recombinant protein (PIP001) was serially diluted
in sodium bicarbonate buffer (pH 9.6) to yield concentrations of 0.01, 0.1, 0.5, 1.0, 5.0, 10, and
100 µg·mL−1, then 100 µL of the antigen solution was added in triplicate to the plate and incubated
at 4 ◦C overnight. The control wells contained no antigen. The plate was aspirated and washed
three times using 200 µL 0.01 M PBS Tween-20 (0.05 v/v). A 200 µL of 1% BSA was then used to
block the plate by incubating at 37 ◦C for 2 h in a Labsystems iEMS Incubator/shaker (Bradenton, FL,
USA). The wash steps were repeated. A detection antibody conjugated with horseradish peroxidase
(HCA 159, 10 µg·mL−1) was added to the wells, and incubated at 37 ◦C for 2 h. The plate was washed
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three times in PBS Tween-20 (0.05 v/v). A 100 µL solution of 3, 3′, 5, 5′ Tetramethylbenzidine/H2O2
was added to the reaction wells, and incubated at room temperature for 15 min in the dark. The
reaction was stopped using 50 µL of 1 M H2SO4, and read at 450 nm on a Varioskan plate reader
(Thermo Fischer Scientific (Hertfordshire, UK).
A Sandwich ELISA assay was then developed, where 100 µL of Pf HRP 2 capture antibody
(HCA 160) was dissolved in 900 µL of 0.1 M sodium bicarbonate buffer (pH 9.6) to give a concentration
of 50 µg·mL−1. Twenty microliters (20 µL) of this solution were deposited in a microtiter plate and
incubated overnight at 4 ◦C. The plate was then washed three times using 200 µL of 0.1 M PBS
Tween-20 (0.05 v/v). Two hundred microliters (200 µL) of 1% BSA was then added to block the plates
by incubating at 37 ◦C for 2 h. The plate was then washed and 100 µL of serial dilution of the Pf HRP
2 antigen was added to the plate as a 0.01, 0.5, 0.1, 1.0, 10, 50, and 100 µg·mL−1 antigen diluted in
PBS (0.01 M). The control wells contained no antigen. The plate was then incubated at 37 ◦C for 2 h.
The plate was washed three times in PBS Tween-20 (0.05 v/v). Two hundred microliters (200 µL) of
Pf HRP 2 detection antibody-HRP (HCA 159) were dissolved in 800 µL of PBST-20 (0.05 v/v) to give
a concentration of 20 µg·mL−1, and incubated at 37 ◦C for 2 h. The plate was washed three times
using 200 µL of 0.01 M PBS Tween-20, (0.05 v/v). One hundred microliters (100 µL) of 3, 3′, 5, 5′
Tetramethylbenzidine were added to the reaction wells, and incubated at room temperature for 15 min
in the dark. The reaction was stopped using 50 µL of 1 M H2SO4 and read at a 450 nm wavelength.
The standard curve and linear regression with the limit of detection were obtained in Microsoft Excel.
The limit of detection (LOD) was calculated as 3 times the SD of the blank measurement plus the
average blank measurement.
2.5. Optimisation of Capture and Detection Antibody on the Sensor’s Surface
A 20 µL capture antibody in concentrations of 10, 20, and 30 µg·mL−1 in sodium bicarbonate buffer
(0.1 M, pH 9.6) was immobilised by physical adsorption on the gold working electrodes (overnight at
4 ◦C) in humid conditions. Prior to the immobilisation of the antibodies, the sensors were cured at
120 ◦C and washed using distilled water. After the immobilisation, the sensors were washed twice
using PBST and dried in a gentle flow of nitrogen. The electrode surface was blocked using 100 µL
of 1:10 milk in PBS (0.01 M) to reduce non-specific binding and incubated for 1 h at 37 ◦C. After each
incubation step, the surface was washed gently with 100 µL PBST. After washing, 30 µg·mL−1 of
Pf HRP 2 antigen prepared in 20 µL of PBS was dropped onto the working electrode and incubated
for 1 h at 37 ◦C. The surface was washed with PBST again. The detection antibody HCA 159P was
diluted to a working strength of 30 µg·mL−1 in 1:40 milk concentrate and incubated on the sensor
for 1 h. The sensors were then washed and assayed by using a volume of 100 µL of the TMB-H2O2
substrate, dropped on the sensor surface covering all three electrodes. The current was then measured
using the potentiostat.
The detection antibody concentration was optimised by repeating the above procedure using
the best concentration of capture antibody obtained in the above experiment (20 µL Pf HRP 2 capture
antibody, 20 µg·mL−1) in sodium bicarbonate buffer (0.1 M, pH 9.6). The capture antibody was
immobilised, and the sensor washed and blocked as above. A 30 µg·mL−1 Pf HRP 2 antigen was
prepared in 1:10 milk PBS, and 10 µL was dropped onto the working electrode. The detection antibody
was used at different concentrations of 10, 20, and 30 µg·mL−1 in 1:40 milk PBS. The experiment was
repeated as above.
2.6. Standard Curve and Limit of Detection
The Pf HRP 2 antigen was assayed using 20 µL of capture antibody with a concentration of
20 µg·mL−1 in sodium bicarbonate buffer (0.1 M, pH 9.6) immobilised on the gold working electrode
and incubated overnight at 4 ºC. Concentrations of 0, 2, 16, 20, 40, 64, 80, and 100 ng·mL−1 of Pf HRP
2 antigen were prepared in 1:10 milk PBS (0.01 M), and 20 µL of the antigen solution was dropped onto
the working electrode. The detection antibody-HRP was diluted to a working strength of 20 µg·mL−1
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in 1:40 milk PBS. The lowest detection limit of the antigen was determined by 3 times the standard
deviation of the blank value plus the average of the blank measurement, and the data were presented
using Microsoft Excel.
2.7. Signal Amplification Using Gold Nanoparticle
Colloidal gold (40 nm) was employed for its large surface area in an attempt to amplify the
sensor’s signal and lower the detection limit of the target protein. The commercial colloidal gold
nanoparticles were investigated using different concentrations of blocking buffer for the optimisation
of the Au nanoparticles’ (AuNP) conjugation to the reporter protein. A 1000 µL quantity of gold colloid
was taken in a 1.5 mL tube, and 0.1 µL of 0.2 M NaOH was added, adjusting the pH to 9.0 [30]. A 100 µL
volume of neat 0.1 mg·mL−1 detection antibody (HCA 159P) was added, and the mixture was shaken
at room temperature for 1 h. The blocking buffer dilutions of 1:5, 1:10, 1:20, and 1:50 BSA and 1:5 and
1:10 milk in PBS were examined as the blocker after the antibodies’ attachment to the nanoparticles.
The tube was then shaken at room temperature for 1 h in the dark and spun at 10,000 rpm for 10 min
(4 ◦C). The supernatant was discarded and the pellet re-suspended in 70 µL PBS (0.01 M) to obtain the
stock AuNP—conjugated to the detection antibody—HRP, which was stored at 4 ◦C. The stock was
diluted 1:5 and 1:10 to produce the amplified signal. Another batch of nanoparticles was also prepared
in a way similar to the above procedure, but by adding extra horseradish peroxidase enzyme (HRP)
after the antibody-HRP attachment. Three microliters (3 µL) of HRP (20 mg·mL−1) were added to
the AuNP antibody-HRP solution and incubated for 1 h at room temperature in a shaker. The tube
was then spun at 10,000 rpm for 10 min (4 ◦C) and the supernatant discarded. The sediment was
re-suspended in 1 mL distilled water and the procedure continued as used above. The principle of the
developed sensor can be seen in Scheme 1.
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2.8. Human Serum Assay
In order to test the sensor for matrix effect, a co ercially available human serum sample was
used and spiked with different concentrations of the biomarker. Tests were then conducted using 100%
human serum sample following the same proc dure as that report d in Sections 2.6 and 2.7.
3. Results and Discussion
3.1. Characterisation of the Screen-Printed Electrodes
In order to make a comparison of the 3 electrodes (JD1, JD2a, and JD2b), electrochemical
characterisation was conducted using cyclic voltammetry. This was to investigate the performance
of the new carbon ink used in the JD2 electrodes, and also to study the effect of the production year
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on the performance of the sensors. All of the electrodes were stored at room temperature in dark
conditions. The experiments were carried out in the presence of potassium ferricyanide, in different
concentrations (0.1, 0.5 and 1 mM) and at different scan rates (10, 20, 50, 70 and 100 mV·s−1) relative
to the on board Ag/AgCl reference electrodes. The cathodic and anodic peak current was used to
calculate the active surface area of the electrodes by employing the Randle–Sevcik equation [28,29].
The ideal ∆E value for a reversible redox reaction of potassium ferricyanide is 56 to 59 mV, and the
ratio between the cathodic and anodic peak is 1 [31,32]. In practice, however, the difference is typically
100 mV and higher [32]. The use of 1 mM potassium ferricyanide resulted in the best reproducibility of
the redox reaction (Data not shown). Figure 1 shows the characterisation of the different sensors using
CV with 1 mM potassium ferricyanide.
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The results showed that even though JD1 was produced in 2010, it performed well when compared
to the JD2 electrodes. It was also noted that the active surface area of the gold working electrode
(Aactive %) in the JD1 was ~10% higher than in the JD2 electrodes (Supplementary information, Table S1).
This could be due to physical/chemical changes taking place in the inks/polymer as the electrodes
become older. Compared to the JD2 electrodes, JD1 suffered from lower reproducibility. The change
in the base carbon ink showed no effect on the sensor’s performance. Both JD2a and JD2b showed
comparative data, and further experiments continued using the JD2b electrodes. In order to study the
optimal potential for the detection system, the current signals generated from TMB/H2O2 with the
HRP-antibody conjugate were analysed using chronoamperometry. The ratio of the signal current
to the background current using step amperometry (−400 mV to +600 mV) of 4 mM TMB and 0.06%
H2O2 with and without the addition of the detection antibody-HRP in a pH 5.0 citrate buffer, 0.1 M
KCl, was calculated. The results showed that the best potential in this system is −0.2 V using JD2
electrodes, and therefore this was selected for future immunosensor developments (Supplementary
information, Figure S1).
3.2. SEM, ESEM and AFM of Bare SPGE
The working electrode of the screen-printed gold sensor was characterised using scanning
electron microscopy (SEM) and environmental scanning electron microscopy (ESEM), which show the
composition of the gold electrode’s surface (Figure 2). The SEM scans showed pinholes in the surface
structure, which were formed as a result of the printing process with a rough granular surface. The
ESEM analysis (Figure 2C) gives a small figure insert with the average of three spectra’s data and
indicates a high percentage of the gold ink (~89.2%) used to produce the sensors with carbon (~9.11)
and oxygen (~1.69).
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The surface roughness of the gold electrode was visualised using atomic force microscopy (AFM)
at 25 and 50 mu (Figure 3). This shows the screen-printed gold working electrode’s topography, similar
to the SEM scans.
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Figure 3. Three-dimensional (3D) surface topography of a bare screen-printed gold electrode (SPGE)
using AFM at (A) 25 mu and (B) 50 mu.
3.3. Development of the Immunoas ay
First, the Pf HRP 2 assay was dev loped using the microtiter plate by a direct and a sandwich assay
format in order to investigate the suitability of the reagents for the detection of Pf HRP 2, before moving
the assay to the sensor’s surface. The direct assay was conducte by immobilising the antigen by
physical adsorption t the plate, nd detecting it using the det ction antibody-enzyme conjugate. Th
sandwich assay u ed the capture antibody mmobilised on the pla e surface, and the antigen was added
in solution using different concentrations. The detection antibody-e zyme was then added to complete
the assay. T re ults for both a says are shown in the Supplementary Information Figures S2 and S3.
The LOD was calculated as 0.56 µg·mL−1 for the direct ELISA and 0.89 µg·mL−1 for the sandwich
ELISA. The results reveal that the HuCAL sandwich pair recognises and interacts with the malar a
protein, and can b used in the developme t of an immunosens r. No further devel pment of
assay r optimisa ion w s c nducted on the ELISA assay, since the aim of the work was to focus on
the sensor’s development.
3.4. Development of PfHRP 2 Immunosensor
Capture antibody optimisation was conducted using a sandwich ELISA format. Concentrations
of 10, 20, and 30 µg· L−1 were added to the sensor’s surface (20 µL in sodium bicarbonate buffer,
0.1 M, pH 9.6) to attach to the sensor using physical adsorption (overnight at 4 ◦C). The electrodes were
then blocked using 100 µL, 1:10 milk in PBS (0.01 M) for 1 h at 37 ◦C, and then washed gently using
PBST buffer. The Pf HRP 2 antigen was then dropped onto the sensor’s surface (20 µL, 30 µg·mL−1)
and incubated for 1 h (37 ◦C), washed, and then the detection antibody-enzyme (20 µL, 30 µg·mL−1)
was added and incubated (1 h, 37 ◦C). The assay was then followed by adding the TMB-H2O2
substrate, and the signal was recorded using a −200 mV potential. TMB-H2O2 was chosen as the
enzyme substrate for the enzyme label horseradish peroxidase (HRP)’s activity deter ination [33].
Furthermore, TMB has superior detection properties than other systems [34–36]. Figure 4A shows that
the best concentration was found to be 20 µg·mL−1 for the capture antibody. The response increased
linearly against antibody concentration up to about the 20 µg·mL−1 concentration level, and after this
point the response was lower, which indicates the saturation of the sensor’s surface. A 20 µg·mL-1
concentration of anti Pf HRP 2 antibody was chosen as the optimum concentration for the capture
antibody, since it was the best compromise between the response and the cost of the antibody.
The detection antibody concentration was then optimised using 20 µg·mL−1 capture antibody
immobilised on the sensor’s surface. The detection antibody-enzy e conjugate as tested at 10, 20,
and 30 µg· L−1 in 1:40 milk PBS and 30 µg·mL−1 antigen. The procedure followed was similar to
that listed above. The results are shown in Figure 4B, with the highest signal recorded at 20 µg·mL−1
also for the detection antibody-HRP concentration.
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The immunosensor was then developed for the detection and quantification of Pf HRP 2. The
optimal capture (20 µg·mL−1) and detection antibody (20 µg·mL−1) concentrations were used with
the JD2 electrodes to conduct a calibration curve. Different Pf HRP 2 antigen concentrations (0, 2, 16,
20, 64, 80, and 100 ng·mL−1) prepared in 1:10 milk/PBS (0.01M) as dilution buffer, and then a set of
experiments was conducted in spiked 100% commercial human serum samples. The assay was run in
triplicate for all of the measurements. The blank contained no antigen for the buffer and the serum
experiments. The results of both assays are shown in Figure 5. The results agree with the range used
by [37] for the detection of PfHRP 2. The effect of tandem repeats in the structure of the protein make
the antigen easy to detect; however, the concentration of the analyte is influenced by the matrix.
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Figure 5. Linear regression analysis of the chronoamperometric response of Pf HRP 2 detection in buffer
(PBS, 0.01M, pH 7.4, spiked with 1–100 ng·mL−1 Pf HRP 2) (A) and 100% serum samples (spiked with
1–100 ng·mL−1 Pf HRP 2) (B) on a JD2 sensor. Measurements were conducted at −0.2 V. Correlation
coefficient and R2 value of 0.9827 for the buffer matrix and 0.98 for the serum matrix (n = 3).
From the data shown in Figure 5A, the limit of detection (LOD) for the buffer samples was
calculated as 2.14 ng·mL−1, and for the spiked human s rum samples (Figure 5B) the LOD as
2.95 ng·mL−1. These results show t at both assays give a similar detection limit, but with lower
readings ac ieved for the serum samples. This is ery encouraging a d indicates that the sensors are
ble to perf rm w ll sing 100% commercial human serum samples. The difference i matrix ffects
th rate of lectro exchange, which occ rs wh n the nalyte is oxi iz d whe a potential differenc
is applied. The lower readings an be du to sm ll proteins in the samples ttachi g to the sensor’s
surface and affecting the electro transf r. The sensitivity and reproducibility of the sensor i this
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assay are shown to be adequate for the detection of the malaria biomarker, since a blood level of
~9.45 ng·mL−1 has been reported to be Plasmodium sp. specific and malaria positive [38–40].
To investigate if we can improve the detection limit further, the detection antibody-HRP was
attached to gold nanoparticles (40 nm) and used in the sandwich assay. Several optimisation
experiments were conducted to achieve the best results before a calibration curve was repeated
with serial dilution of the antigen in buffer first, and then the experiments were repeated in 100%
commercial human serum samples. The full procedures are listed in Section 2.7. Figure 6 shows
the linear regression of the results achieved using the amplified assay with the gold nanoparticles
conjugated detection antibody-HRP alone, without the addition of free enzymes to attach to the
gold nanoparticles.
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From the above data, an LOD of 36 pg·mL−1 was obtained in the amplified buffer samples with
an R2 value of 0.955 (Figure 6A). An LOD of 40 pg·mL−1 was also obtained in the amplified 100%
serum samples (Figure 6B). The AuNP results gave excellent sensitivity and limit of detection without
the use of additional free enzymes (horseradish peroxidase) to load the particles. The best AuNP
conjugate stock dilution used was 1:10 milk in PBS, and also blocking with milk proteins. The serum
proteins in the samples in this assay also showed a similar trend to the non-amplified assay, in that
similar responses where achieved to the buffer samples. Table 1 shows some of the different biosensor
technology for detecting PfHRP 2, and their detection limits. These are comparable to the limits
achieved using our sensor. Our work showed that a proof of concept sensor was developed and this
can achieve a much lower detection limit than is required for malaria’s positive detection in blood
samples. Further work will be done to examine the sensor in patient serum samples to confirm the
results achieved in this work.
Table 1. Different biosensor technology for detecting PfHRP 2, and their detection limits.
Analyte Assay Principle Range Detection Limit References
Pf HRP 2 SPR - 5.6 pg·mL−1 [25]
Pf HRP 2 Carbon SPE modified withMWCN and Au/MWCN - 8 ng·mL
−1 [37]
Pf HRP 2 Carbon SPE modified withAuNPs/Al2 3sol–gel
- - [41]
Pf HRP 2 Graphite–epoxy compositemagneto electrodes - 0.36 ng·mL
−1 [42]
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Table 1. Cont.
Analyte Assay Principle Range Detection Limit References
Pf HRP 2 Polydimethylsiloxanemicrofluidic chips - 16 ng·mL
−1 [43]
Pf HRP 2 Carbon nanofiber forest grown onglass microballons 0.01–10 ng·mL
−1 0.025 ng·mL−1 [44]
Pf HRP 2
Mercaptopropylphosphonic acid
functionalized copper doped zinc
oxide nanofibers
10 ag·mL−1–
10 µg·mL−1 6.8 ag·mL
−1 [45]
Pf HRP 2
Low electrocatalytic indium tin
oxide (ITO) on glass electrodes;
APTES-glutaraldehyde modified
1 pg·mL−1–
100 ng·mL−1 2.2 pg·mL
−1 [46]
4. Conclusions
An immunosensor has been successfully developed using a sandwich ELISA assay on JD2 gold
screen-printed electrodes. Milk concentrate was used as the blocking protein, as it reduced non-specific
binding on the electrode surface. With both malaria antigen and antibodies being very expensive, care
had to be taken in designing the experiments to achieve optimised results. An ELISA test was first
developed to check the affinity of both antibodies toward the antigen Pf HRP 2. An immunosensor
was then developed and optimised with electrochemical measurements that produced a 2.14 ng·mL−1
detection limit for the buffer samples, which is better than the ELISA assay developed in this work.
Spiked 100% serum samples also achieved a very good LOD of 2.95 ng·mL−1. An amplified signal is
also achievable using the sensor with AuNPs conjugated to the detection antibody-enzyme. Signal
amplification using gold nanoparticles gave an LOD of 36 pg·mL−1, while the serum assay gave an
LOD of 40 pg·mL−1. The developed immunosensor offers a highly sensitive, portable, and low cost
method of detecting Plasmodium falciparum histidine-rich protein 2. Future experiments will look at
real samples analysis using patient serum samples.
Supplementary Materials: Figure S1: Optimum potential determination by step potential of TMB/H2O2 system
with antibody-HRP on JD2 electrodes. The results shown are after subtracting the signal with no enzyme, Figure S2:
(A) Standard curve of absorbance versus antigen concentration in a direct ELISA assay, (B) linear regression with
correlation coefficient and R2 value of 0.9612, limit of detection is 0.56 µg·mL−1, Figure S3: (A) Standard curve
of absorbance versus antigen concentration in a Sandwich ELISA assay, (B) linear regression with correlation
coefficient and R2 value of 0.9755. Limit of detection is 0.89 µg·mL−1, Table S1: Overview of cyclic voltammetric
analyses of the three electrodes, JD1, JD2a and JD2b at 20 mV·s−1, using 1 mM potassium ferricyanide solution in
0.1 M KCl, n = 5.
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